New hope for HER2+ breast cancer: zanidatamab plus chemo aims for complete tumor disappearance before surgery

NCT ID NCT07102381

Recruiting now Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 33 times

Summary

This study tests whether adding zanidatamab to standard chemotherapy can completely eliminate cancer in the breast and armpit before surgery in people with early-stage HER2-positive breast cancer. About 125 participants with stage II or III disease will receive the combination and then have surgery to check for any remaining cancer. The main goal is to see how many achieve a pathologic complete response (no cancer found).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Accellacare of McFarland
RECRUITING

Ames, Iowa, 50010, United States
Astera Cancer Care (Formerly Regional Cancer Care Associates)
RECRUITING

East Brunswick, New Jersey, 08816, United States
Cancer Partners of Nebraska
RECRUITING

Lincoln, Nebraska, 68516, United States
Hematology Oncology Associates of Central New York
RECRUITING

Camillus, New York, 13031, United States
Hosp Beata María Ana de Jesús
RECRUITING

Madrid, 28007, Spain
Hospital Clínico San Cecilio
RECRUITING

Granada, Andalusia, 18007, Spain
LSU Health Sciences Center
RECRUITING

Shreveport, Louisiana, 71103, United States
Maryland Oncology Hematology
RECRUITING

Laurel, Maryland, 20707, United States
Medical Oncology Hematology Associates
RECRUITING

Newark, New Jersey, 19713, United States
Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68124, United States
New England Cancer Specialists
RECRUITING

Scarborough, Maine, 04074, United States
Northwest Cancer Specialists
RECRUITING

Vancouver, Washington, 98648, United States
Northwest Medical Specialties
RECRUITING

Puyallup, Washington, 98373, United States
Oncology Institute
RECRUITING

Long Beach, California, 90805, United States
Ospedale San Raffaele
RECRUITING

Milan, Lombardy, 20132, Italy
Rocky Mountain Cancer Centers
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute (Nashville)
RECRUITING

Nashville, Tennessee, 37203, United States
Shenandoah Oncology
RECRUITING

Winchester, Virginia, 22601, United States
Texas Oncology DFW
RECRUITING

Dallas, Texas, 75246, United States
Texas Oncology Gulf Coast
RECRUITING

Houston, Texas, 77024, United States
The Oncology Institute
RECRUITING

Lakeland, Florida, 33812, United States
The University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53706, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
Virginia Oncology Associates
RECRUITING

Norfolk, Virginia, 23502, United States
Álvaro Cunqueiro Hospital
RECRUITING

Vigo, Galicia, 36312, Spain

Conditions

Explore the condition pages connected to this study.

BREAST CANCER HER2-POSITIVE BREAST CANCER